HCW Biologics Inc. 8-K

What Happened
HCW Biologics Inc. announced in an 8-K that Nasdaq notified the company on March 26, 2026 that its shares had fallen below the $1 minimum bid price for 30 consecutive business days, triggering a listing deficiency under Nasdaq Listing Rule 5550(a)(2). Because the company completed a 1-for-40 reverse stock split on April 11, 2025, it was not eligible for the usual 180-calendar day cure period. After a hearing on May 5, 2026, the Nasdaq Hearings Panel granted an exception on May 29, 2026 giving HCW Biologics time to regain compliance.

Key Details

• Nasdaq finding: below $1 per share for 30 consecutive business days (notice dated March 26, 2026).
• Required cure: on or before July 29, 2026, exhibit a bid price ≥ $1 for 20 consecutive trading days.
• Short-term risk: if deficient with the bid price prior to September 22, 2026, the company will be immediately delisted; other rule deficiencies before that date get a 7-day window to present a cure plan.
• Monitoring: if HCW regains compliance, Nasdaq intends to impose a Discretionary Panel Monitor for one additional year (per Listing Rule 5815(d)(4)(A)).

Why It Matters
This filing affects HCW Biologics’ continued listing on Nasdaq — failing to meet the $1 bid-price requirement can lead to delisting, which typically reduces liquidity and can limit investor access. The company has a defined, short timetable (must show 20 consecutive trading days at or above $1 by July 29, 2026) and faces heightened scrutiny through a likely one-year panel monitor if it cures the deficiency. Investors should monitor the company’s stock price, any corporate actions (e.g., financings, reverse splits, or other measures) and company announcements for developments that affect compliance.